loader
Please Wait
Applying Filters...

Annual Sales of MolPort-001-641-024 reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 47Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Apriso

02 3Asacol

03 4Asacol/Delzicol

04 1Canasa

05 4Canasa/Salofalk

06 1Delzicol

07 3Etiasa

08 7Lialda/Mezavant

09 2Lialda/Mezavant/Mesavancol

10 2Mezavant/Mesavancol/Lialda

11 7Pentasa

PharmaCompass

01

Brand Name : Asacol/Delzicol

arrow
Formnext Forum
Not Confirmed

Mesalazine

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2017 Revenue in Millions : 246

2016 Revenue in Millions : 415

Growth (%) : -41

Abbvie CB

02

Brand Name : Canasa/Salofalk

arrow
Formnext Forum
Not Confirmed

Mesalazine

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2017 Revenue in Millions : 181

2016 Revenue in Millions : 196

Growth (%) : -8

Abbvie CB

03

Brand Name : Asacol/Delzicol

arrow
Formnext Forum
Not Confirmed

Mesalazine

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2018 Revenue in Millions : 177

2017 Revenue in Millions : 246

Growth (%) : -28%

Abbvie CB

04

Brand Name : Asacol/Delzicol

arrow
Formnext Forum
Not Confirmed

Mesalazine

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2016 Revenue in Millions : 415

2015 Revenue in Millions : 618

Growth (%) : -33

Abbvie CB

05

Brand Name : Canasa/Salofalk

arrow
Formnext Forum
Not Confirmed

Mesalazine

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2018 Revenue in Millions : 187

2017 Revenue in Millions : 181

Growth (%) : 3%

Abbvie CB

06

Brand Name : Canasa/Salofalk

arrow
Formnext Forum
Not Confirmed

Mesalazine

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2016 Revenue in Millions : 196

2015 Revenue in Millions : 156

Growth (%) : 26

Abbvie CB

07

Brand Name : Asacol/Delzicol

arrow
Formnext Forum
Not Confirmed

Mesalazine

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2019 Revenue in Millions : 113

2018 Revenue in Millions : 177

Growth (%) : -36

Abbvie CB

08

Brand Name : Canasa/Salofalk

arrow
Formnext Forum
Not Confirmed

Mesalazine

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2019 Revenue in Millions : 48

2018 Revenue in Millions : 187

Growth (%) : -74

Abbvie CB

09

Brand Name : Pentasa

Mesalamine

arrow
Formnext Forum
Not Confirmed

Brand Name : Pentasa

arrow
Formnext Forum
Not Confirmed

Mesalamine

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2019 Revenue in Millions : 232

2018 Revenue in Millions : 0

Growth (%) : N/A

blank

10

Brand Name : Mezavant/Mesavancol/Lialda

Mesalazine

arrow
Formnext Forum
Not Confirmed

Brand Name : Mezavant/Mesavancol/Lialda

arrow
Formnext Forum
Not Confirmed

Mesalazine

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2020 Revenue in Millions : 33

2019 Revenue in Millions : 26

Growth (%) : 27

blank